Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Total Current Liabilities: 2011-2024

Historic Total Current Liabilities for Capricor Therapeutics (CAPR) over the last 14 years, with Dec 2024 value amounting to $21.0 million.

  • Capricor Therapeutics' Total Current Liabilities rose 37.47% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 37.47%. This contributed to the annual value of $21.0 million for FY2024, which is 32.76% down from last year.
  • Per Capricor Therapeutics' latest filing, its Total Current Liabilities stood at $21.0 million for FY2024, which was down 32.76% from $31.3 million recorded in FY2023.
  • In the past 5 years, Capricor Therapeutics' Total Current Liabilities registered a high of $31.3 million during FY2023, and its lowest value of $3.0 million during FY2020.
  • For the 3-year period, Capricor Therapeutics' Total Current Liabilities averaged around $25.3 million, with its median value being $23.6 million (2022).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 470.63% in 2022, then slumped by 32.76% in 2024.
  • Over the past 5 years, Capricor Therapeutics' Total Current Liabilities (Yearly) stood at $3.0 million in 2020, then soared by 39.11% to $4.1 million in 2021, then spiked by 470.63% to $23.6 million in 2022, then soared by 32.57% to $31.3 million in 2023, then tumbled by 32.76% to $21.0 million in 2024.